PriceTargets.com logo

VYNE Therapeutics - VYNE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.50
  • Forecasted Upside: 455.56%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.27 As of 02/7/2023 01:00 AM ET
▲ +0.01 (3.85%)

This chart shows the closing price for VYNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VYNE Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYNE

Analyst Price Target is $1.50
▲ +455.56% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for VYNE Therapeutics in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 455.56% upside from the last price of $0.27.

This chart shows the closing price for VYNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in VYNE Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/12/2022Lifesci CapitalDowngradeOutperform ➝ Market PerformLow
8/10/2022HC WainwrightLower TargetBuy$7.00 ➝ $1.50Low
6/17/2022HC WainwrightReiterated RatingBuy$7.00Low
3/18/2022Cantor FitzgeraldReiterated RatingOverweightLow
12/6/2021HC WainwrightReiterated RatingBuy$7.00High
8/16/2021HC WainwrightDowngradeBuy ➝ NeutralHigh
8/13/2021Northland SecuritiesLower TargetSell ➝ Outperform$12.00 ➝ $6.00High
5/7/2021HC WainwrightLower TargetBuy$14.00 ➝ $11.00High
12/17/2020Maxim GroupReiterated RatingPositiveHigh
10/5/2020HC WainwrightBoost TargetBuy$12.00 ➝ $14.00High
10/2/2020Lifesci CapitalReiterated RatingOutperformHigh
10/2/2020Northland SecuritiesReiterated RatingBuy$24.00Low
8/7/2020HC WainwrightLower TargetBuy$14.00 ➝ $12.00Low
8/6/2020Ci CapitalReiterated RatingBuy$28.00Low
8/4/2020Northland SecuritiesReiterated RatingBuyHigh
6/1/2020Northland SecuritiesBoost TargetOutperform$14.00 ➝ $24.00Low
6/1/2020HC WainwrightBoost TargetBuy$10.00 ➝ $14.00Low
5/21/2020Northland SecuritiesInitiated CoverageOutperform$14.00High
5/13/2020BarclaysBoost TargetOverweight$8.00 ➝ $12.00High
5/12/2020HC WainwrightBoost TargetBuy$8.00 ➝ $10.00High
4/7/2020BarclaysLower TargetOverweight$32.00 ➝ $8.00High
4/7/2020HC WainwrightLower TargetBuy$32.00 ➝ $8.00High
3/25/2020BarclaysInitiated CoverageOverweight$32.00Medium
3/11/2020Bank of AmericaInitiated CoverageBuy$32.00High
2/27/2020HC WainwrightLower TargetBuy$40.00 ➝ $36.00High
10/18/2019HC WainwrightInitiated CoverageBuy$44.00High
5/2/2019Cantor FitzgeraldReiterated RatingBuy$100.00Medium
2/27/2019Cantor FitzgeraldReiterated RatingBuy$100.00Low
11/7/2018Cantor FitzgeraldReiterated RatingBuy$100.00Medium
10/9/2018Jefferies Financial GroupLower TargetHold$28.00Low
10/8/2018Cantor FitzgeraldReiterated RatingBuy$100.00High
9/6/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$100.00Medium
7/24/2018Roth CapitalInitiated CoverageBuy$116.00High
7/24/2018KeyCorpInitiated CoverageBuyHigh
4/25/2018GuggenheimReiterated RatingBuy$44.00High
4/9/2018Jefferies Financial GroupDowngradeBuy ➝ HoldN/A
2/20/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$176.00 ➝ $176.00High
2/20/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$192.00High
2/20/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$164.00High
2/19/2018GuggenheimInitiated CoverageBuy ➝ Buy$208.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

VYNE Therapeutics logo
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded on October 21, and is headquartered in Bridgewater, NJ.
Read More

Today's Range

Now: $0.27
Low: $0.26
High: $0.29

50 Day Range

MA: $0.21
Low: $0.12
High: $0.28

52 Week Range

Now: $0.27
Low: $0.11
High: $0.79

Volume

524,380 shs

Average Volume

2,711,799 shs

Market Capitalization

$15.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Frequently Asked Questions

What sell-side analysts currently cover shares of VYNE Therapeutics?

The following Wall Street analysts have issued reports on VYNE Therapeutics in the last year: Cantor Fitzgerald, HC Wainwright, and Lifesci Capital.
View the latest analyst ratings for VYNE.

What is the current price target for VYNE Therapeutics?

1 Wall Street analysts have set twelve-month price targets for VYNE Therapeutics in the last year. Their average twelve-month price target is $1.50, suggesting a possible upside of 455.6%. HC Wainwright has the highest price target set, predicting VYNE will reach $1.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.50 for VYNE Therapeutics in the next year.
View the latest price targets for VYNE.

What is the current consensus analyst rating for VYNE Therapeutics?

VYNE Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYNE will outperform the market and that investors should add to their positions of VYNE Therapeutics.
View the latest ratings for VYNE.

What other companies compete with VYNE Therapeutics?

Other companies that are similar to VYNE Therapeutics include Processa Pharmaceuticals, Cellectar Biosciences, RedHill Biopharma, Evoke Pharma and Aridis Pharmaceuticals. Learn More about companies similar to VYNE Therapeutics.

How do I contact VYNE Therapeutics' investor relations team?

VYNE Therapeutics' physical mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The company's listed phone number is (800) 755-7936 and its investor relations email address is [email protected] The official website for VYNE Therapeutics is vynetherapeutics.com. Learn More about contacing VYNE Therapeutics investor relations.